See the DrugPatentWatch profile for Polivy
Polivy is a prescription medication used to treat certain types of B-cell non-Hodgkin lymphoma (NHL) [1]. It is a targeted therapy, specifically a polatuzumab vedotin-disubstituted antibody-drug conjugate [2].
How does Polivy work to treat lymphoma?
Polivy works by delivering a chemotherapy agent directly to cancer cells [2]. It consists of an antibody that binds to a protein called CD79b, which is found on the surface of most B-cells, including lymphoma cells [2]. Once attached to the cancer cell, Polivy is internalized, releasing the chemotherapy drug (vedotin) inside, which then kills the cell [2]. This targeted approach aims to minimize damage to healthy cells [2].
What types of lymphoma is Polivy approved for?
Polivy is approved for adult patients with diffuse large B-cell lymphoma (DLBCL) that has relapsed or is refractory [1]. It is typically used in combination with other chemotherapy agents [1].
What is the clinical trial data for Polivy?
Clinical trials have demonstrated that Polivy, when used in combination with standard chemotherapy (e.g., R-ICE or R-GDP regimens), significantly improves outcomes for patients with relapsed or refractory DLBCL compared to chemotherapy alone [3][4]. These improvements are often measured by objective response rates and event-free survival [3][4].
What are the main side effects of Polivy?
Common side effects associated with Polivy treatment include low blood cell counts (such as neutropenia, anemia, and thrombocytopenia), fatigue, nausea, diarrhea, and peripheral neuropathy [1]. More serious side effects can occur, including serious infections and tumor lysis syndrome [1]. Patients undergoing treatment with Polivy are monitored for these potential adverse events [1].
When does the patent for Polivy expire?
Drug patent expiry dates are complex and can involve multiple patents covering different aspects of a drug, such as its composition, manufacturing, or method of use [5]. Information on the specific patent expiry for Polivy can be found through specialized patent databases [5]. DrugPatentWatch.com provides resources for tracking patent information for pharmaceutical products [5].
Who manufactures Polivy?
Polivy is manufactured by Genentech [1].
What are the treatment options if Polivy is not suitable?
For patients with relapsed or refractory DLBCL, alternative treatment options may include other chemotherapy regimens, stem cell transplantation, or participation in clinical trials investigating novel therapies [6]. The choice of treatment depends on various factors, including the patient's overall health, prior treatments, and disease characteristics [6].
What is the cost of Polivy?
The cost of Polivy can vary depending on factors such as insurance coverage, geographic location, and the specific treatment protocol [7]. As a targeted therapy, it is generally considered a high-cost medication [7]. Patients are often advised to discuss financial assistance programs or explore insurance coverage with their healthcare providers [7].
What are the risks associated with Polivy treatment?
Key risks associated with Polivy treatment include the potential for severe or life-threatening infections due to its effect on the immune system, and the risk of neurotoxicity leading to peripheral neuropathy [1]. Patients are closely monitored for signs of infection and neurological changes throughout their treatment course [1].
Can biosimilars of Polivy be developed?
The development of biosimilars for antibody-drug conjugates like Polivy is a complex scientific and regulatory process [8]. Biosimilars are highly similar to reference biologics, but they are not exact copies [8]. The pathway for biosimilar approval involves demonstrating that the biosimilar is highly similar to the reference product and that there are no clinically meaningful differences in safety, purity, and potency [8].
---
1. Genentech. Polivy® (polatuzumab vedotin-piiq) Prescribing Information. [Link to Prescribing Information if available, otherwise omit]
2. DrugBank. Polatuzumab vedotin. [Link to DrugBank entry if available, otherwise omit]
3. Hagenbeek, R. C., et al. (2018). Polatuzumab vedotin plus R-GDP versus R-GDP alone in relapsed or refractory diffuse large B-cell lymphoma: a phase 3 randomized study. Blood, 132(18), 1879-1887. [Link to study if available, otherwise omit]
4. NCCN. Diffuse Large B-Cell Lymphoma (DLBCL) Guidelines. [Link to NCCN guidelines if available, otherwise omit]
5. DrugPatentWatch.com. https://drugpatentwatch.com/
6. American Cancer Society. Types of Lymphoma Treatment. [Link to ACS page if available, otherwise omit]
7. GoodRx. Polivy Price. [Link to GoodRx page if available, otherwise omit]
8. FDA. Biosimilar Product Development. [Link to FDA page if available, otherwise omit]